Evidence map›Paper›PMID 30250408›Full record

ArticleClinical proteomics2018

Proteomic analysis identifies highly expressed plasma membrane proteins for detection and therapeutic targeting of specific breast cancer subtypes.

Yvonne S Ziegler, James J Moresco, Patricia G Tu, John R Yates, Ann M Nardulli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical proteomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yvonne S Ziegler1Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL USA.ORCID 0000-0001-6811-7457
James J Moresco2Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA USA.
Patricia G Tu2Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA USA.
John R Yates2Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA USA.
Ann M Nardulli1Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL USA.
Scripps Research Institute · USUniversity of Illinois Urbana-Champaign · US

Funding

TrainingP41GM103533 · NIGMS · UNIVERSITY OF WASHINGTON · PI YATES III, JOHN R · 2012 to 2021
$20.7M
INTERACTION OF THE ESTROGEN RECEPTOR WITH DNAR01DK053884 · NIDDK · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI NARDULLI, ANN · 1999 to 2014
$4.0M
Genetic Regulation of the Response to Dietary RestrictionR01AG027463 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI DILLIN, ANDREW G · 2008 to 2012
$2.4M
NIA NIH HHS R01 AG027463NIDDK NIH HHS R01 DK053884NIGMS NIH HHS P41 GM103533
6 · The paper itself

Abstract

In recent years, there has been an emphasis on personalizing breast cancer treatment in order to avoid the debilitating side effects caused by broad-spectrum chemotherapeutic drug treatment. Development of personalized medicine requires the identification of proteins that are expressed by individual tumors. Herein, we reveal the identity of plasma membrane proteins that are overexpressed in estrogen receptor α-positive, HER2-positive, and triple negative breast cancer cells. The proteins we identified are involved in maintaining protein structure, intracellular homeostasis, and cellular architecture; enhancing cell proliferation and invasion; and influencing cell migration. These proteins may be useful for breast cancer detection and/or treatment.

Indexed as

Diagnostic markersEstrogen receptor α-positive breast cancerHER2-positive breast cancerIndividualized medicinePlasma membrane proteinsProteomic analysisTriple negative breast cancer

Identifiers

PMID30250408
PMCPMC6145347
OpenAlexW2890251800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.